ESMO

News

ESMO: J&J’s Tagrisso challenge, and other highlights

With Europe’s premier cancer congress ESMO now finished, we close our coverage with a look at some other important new studies that generated a buzz at the show.

News

ESMO: Can BioNTech’s revved-up CAR-T hit solid tumours?

CAR-T therapies have transformed the treatment of some haematological cancers, but haven’t made much headway for solid tumours – although BioNTech thinks it may have the k

News

ESMO: Survival data mars Pluvicto prostate cancer trial

Novartis’ highly-touted radionuclide therapy Pluvicto met its primary endpoint in a phase 3 trial as a second-line therapy for PSMA-positive metastatic castration-resistan

News

ESMO: Trials end 20-year hiatus in cervical cancer therapy

Amid all the new high-tech therapies on display at the ESMO cancer conference, a study funded by Cancer Research UK has shown what can be achieved with cheap generic drugs

News

ESMO: Immunotherapy combos extend lives in bladder cancer

In the last decade, immunotherapy with PD-1/PD-L1 inhibitors has transformed the treatment of relapsed urothelial carcinoma (UC), the most common form of bladder cancer.

News

ESMO: Roche’s Alecensa claims a first in ALK-positive NSCLC

Roche’s Alecensa has become the first drug in the ALK inhibitor class to significantly improve disease-free survival across all disease stages in a phase 3 trial involving

ESMO: J&J’s Tagrisso challenge, and other highlights

ESMO: Can BioNTech’s revved-up CAR-T hit solid tumours?

ESMO: Survival data mars Pluvicto prostate cancer trial

ESMO: Trials end 20-year hiatus in cervical cancer therapy

ESMO: Immunotherapy combos extend lives in bladder cancer

ESMO: Roche’s Alecensa claims a first in ALK-positive NSCLC

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

ESMO

Editor's Picks